ArticleInternational journal of cardiology. Heart & vasculature2025
A nationwide analysis of resource utilization and safety in patients undergoing mitral transcatheter edge-to-edge repair.
Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter edge-to-edge repair (TEER) for mitral regurgitation has rapidly progressed. The MitraClip® system underwent stepwise improvements between 2016 and 2019 (second to fourth generation). However, real-world data on Methods: Primary outcomes (healthcare resource utilization) included hospital length of stay (LOS), adverse discharge to a short-term hospital or skilled nursing facility and hospital costs. Secondary outcomes (safety) were in-hospital mortality and post-procedural complications. Results: A total of 5,212 adults underwent mitral TEER. Mean age was 77.7 (±10.1) years; 3,645 patients (69.9 %) were over 75 years. Median Charlson Comorbidity Index was 3 [IQR 1-4], number of cardiovascular risk factors 3 [2-4], CHA Conclusion: Mitral TEER has become safer and more efficient due to technological advances, operator experience and centralized care. Caution is advised in highly comorbid patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.